SNY Stock Recent News

Private equity firm Clayton Dubilier & Rice (CD&R) is nearing a deal to acquire Sanofi's consumer health unit for about 15 billion euros ($16.4 billion), Bloomberg News reported on Thursday.

Drug developer Denali Therapeutics said on Thursday its partner Sanofi has discontinued a mid-stage study testing their experimental drug to treat multiple sclerosis as it failed to meet the main and secondary goals.

Italian pharma group Recordati said on Friday it would buy from Sanofi the global rights to a drug used to treat cold agglutinin disease (CAD), a rare autoimmune disorder, for $825 million.

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Availability of the Q3 2024 Aide mémoire Paris, France – September 26, 2024. Sanofi announced today that its Q3 2024 Aide mémoire is available on the "Investors" page of the company's website: Third quarter 2024 results (sanofi.com) As for each quarter, Sanofi prepared this document to assist in the financial modelling of the Group's quarterly results.

On Monday, Sanofi SA SNY agreed to make a $27 million strategic investment in Ventyx Biosciences Inc VTYX.

Sarclisa approved in the US as the first anti-CD38 therapy in combination with standard-of-care treatment for adult patients with newly diagnosed multiple myeloma not eligible for transplant

Sanofi won approval for the use of a drug combination with its Sarclisa infusion to treat certain types of newly diagnosed multiple myeloma, where it has previously been used only after standard treatments have failed, the U.S. Food and Drug Administration said on Friday.

SNY's reasonable valuation, rising estimates, improving top line and positive pipeline progress are good enough reasons to stay invested in the stock.

NEW YORK, Sept. 17, 2024 /PRNewswire/ -- Report on how AI is driving market transformation- The global squalene market size is estimated to grow by USD 62.9 mn from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of over 6.79% during the forecast period. Increasing acceptance of uva/b filters in sunscreens and sun protection cosmetics is driving market growth, with a trend towards squalene derived from renewable resources. However, stringent safety regulations on uv sun care products poses a challenge. Key market players include Amyris Inc., ARISTA INDUSTRIES, BOCSCI Inc., Cibus, Croda International Plc, Evonik Industries AG, Gracefruit Ltd., KISHIMOTO SPECIAL LIVER OIL CO. LTD., KURARAY Co. Ltd., LBB Specialties LLC, MacroCare Tech Ltd., Majestic Mountain Sage Inc., Maruha Nichiro Corp., Maypro Group, Micro Capsule Technologies, New Zealand Green Health Ltd., Parchem Fine and Specialty Chemicals Inc., Seadragon, Sophim, and VESTAN. Key insights into market